Marker Therapeutics, Inc.

Monthly Archives: February 2016

TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart – Next-Generation T-Cell Vaccine

…Proprietary DNA Expression Vector Technology Developed at TapImmune’s Laboratories

PolyStart to Move into Clinical Trials and Expand TapImmune‘s Development Pipeline

TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today that it has received a Notice of Allowance from the U.S.

Read More

TapImmune Sponsors 26.2 With DONNA Marathon for Breast Cancer Research and Care

…https://www.markertherapeutics.com/wp-content/uploads/2016/02/Donna-Foundation_295x166.jpg

Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016

JACKSONVILLE, FLORIDA, February 10, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced the Company is a proud sponsor of 26.2 with DONNA, a non-profit organization dedicated to funding groundbreaking breast cancer research and providing assistance to women and men who have been diagnosed with breast cancer.

Read More

TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer

…TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for its cancer vaccine TPIV 200 in the treatment of ovarian cancer.

Read More